Stock Ratings / Health Care / RAPP / options

VSTM (24) AMPH (71) AVLN (49) SPTX (56) ⌘ Pro Terminal →

Rapport Therapeutics Inc. (RAPP) Options Positioning, Max Pain & Unusual Sweeps

$24.21 +7.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $24.50

Rapport Therapeutics Inc. (RAPP) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $1.16B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $24.50 (+1.18%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RAPP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY RAPP SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 37.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$30.65-10% Next Q

Q2 (-2Q)

Grade D$27.57-5.9% Next Q

Q3 (-1Q)

Grade D$25.93-6.6% Next Q

Current

Grade D-$24.21-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RAPP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RAPP currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($36.70) and Max Pain ($25.42) forces dealer call-delta covering toward $55.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RAPP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RAPP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (RAPP)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for RAPP.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RAPP)

✓Walkthrough of RAPP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RAPP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.92%🛡️ HOLDING TREND SUPPORT

2026-10-30O $23.94H $25.43L $23.86C $24.21VOL 923.3K

RES: $60.11SUP: $21.85SMA50: $36.70SMA200: $35.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RAPP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RAPP Butterfly Map → + Track RAPP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RAPP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RAPP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RAPP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RAPP)

Health Care Rank #544 of 1016 ⚔️ VSTM vs RAPP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RAPP vs. VSTM, AMPH, AVLN, SPTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rapport Therapeutics Inc. (RAPP) ranks #544 by composite RQD confidence (43/100, grade D-) and #342 by equity capitalization ($1.16B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with RAPP at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RAPP ACTIVE Rapport Therapeutics Inc.	D-	43/100	—	—	-22.9%	+7.60%	$1.16B	Benchmark Subject
VSTM Verastem Inc.	E	24/100	—	—	-35.0%	-1.78%	$1.17B	/vstm-vs-rapp →
AMPH Amphastar Pharmaceuticals Inc.	B-	71/100	11.7x	49.5%	9.0%	+2.28%	$1.15B	/amph-vs-rapp →
AVLN Avalyn Pharma Inc.	D	49/100	—	—	—	-0.12%	$1.14B	/avln-vs-rapp →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-rapp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002012593

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapport Therapeutics Inc. (RAPP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$111.5M, operating cash flow of -$87.5M, and free cash flow of -$88.1M (-31.0% YoY). On the balance sheet, RAPP closed FY2025 with $512.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$111.5M	-$87.5M	-$88.1M	$512.4M	—
FY2024 (FY)	2024-12-31	$0	-$78.3M	-$64.8M	-$67.2M	$314.9M	—
FY2023 (FY)	2023-12-31	$0	-$34.8M	-$27.2M	-$27.2M	—	—

3. RAPP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rapport Therapeutics Inc. (NASDAQ: RAPP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $24.21 (+7.60% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RAPP ranks #544 in composite RQD confidence.

How does RAPP compare to VSTM and AMPH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RAPP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.9%. By comparison, VSTM (Verastem Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.17B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.15B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RAPP?

Per RAPP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002012593), Rapport Therapeutics Inc. generated $0 in revenue, -$111.5M in net income, and -$88.1M in free cash flow against $512.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RAPP trading relative to its 50-day, 200-day, and 52-week technical levels?

RAPP last traded at $24.21 (+7.60% on volume of 3,096,941 shares), positioning the stock -34.03% below its 50-day simple moving average ($36.70) and -32.09% below its 200-day simple moving average ($35.65). Across its 52-week range of $22.06 to $52.93, RAPP sits at the 7.0% percentile with a 14-day RSI of 37.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($21.18 to $27.24).

RAPP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is RAPP's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for RAPP.

Direct Sub-Reports: RAPP RQD Cockpit RAPP 12M Forecast RAPP Earnings & Move RAPP Dividends & DRIP RAPP Insiders & 13F RAPP Whale Options RAPP Profit Sankey RAPP News & Why